Associations - PD-L1 expression

PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval FDA - 1 week	atezolizumab Sensitive: A1 - Approval FDA - 1 week
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval FDA - 1 week	pembrolizumab + bevacizumab Sensitive: A1 - Approval FDA - 1 week
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	avelumab + axitinib Sensitive: A1 - Approval	avelumab + axitinib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Esophageal Cancer Esophageal Cancer	PD-L1 expression PD-L1 expression	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Oral Cancer Oral Cancer	PD-L1 expression PD-L1 expression	Oral Cancer Oral Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Oropharyngeal Cancer Oropharyngeal Cancer	PD-L1 expression PD-L1 expression	Oropharyngeal Cancer Oropharyngeal Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	ADX-2191 Sensitive: A2 - Guideline	ADX-2191 Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline	cetuximab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Gastric Adenocarcinoma Gastric Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastric Adenocarcinoma Gastric Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	atezolizumab Sensitive: A2 - Guideline	atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline	atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Head and Neck Cancer Head and Neck Cancer	PD-L1 expression PD-L1 expression	Head and Neck Cancer Head and Neck Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A2 - Guideline	bevacizumab + atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline	bevacizumab + atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Vulvar Cancer Vulvar Cancer	PD-L1 expression PD-L1 expression	Vulvar Cancer Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Gastric Adenocarcinoma Gastric Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastric Adenocarcinoma Gastric Adenocarcinoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	Immunotherapy Sensitive: A2 - Guideline	Immunotherapy Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	PD-L1 expression PD-L1 expression	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials	pembrolizumab + axitinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Small Cell Lung Cancer Small Cell Lung Cancer	PD-L1 expression PD-L1 expression	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Melanoma Melanoma	PD-L1 expression PD-L1 expression	Melanoma Melanoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	CS1001 Sensitive: B - Late Trials	CS1001 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	sintilimab Sensitive: B - Late Trials	sintilimab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	bevacizumab + atezolizumab Resistant: B - Late Trials	bevacizumab + atezolizumab Resistant: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: B - Late Trials	tislelizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	nivolumab + cabozantinib tablet Sensitive: B - Late Trials	nivolumab + cabozantinib tablet Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	avelumab Sensitive: B - Late Trials	avelumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Melanoma Melanoma	PD-L1 expression PD-L1 expression	Melanoma Melanoma	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Melanoma Melanoma	PD-L1 expression PD-L1 expression	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	pembrolizumab + axitinib Sensitive: B - Late Trials	pembrolizumab + axitinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	CPB Sensitive: B - Late Trials	CPB Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Cutaneous Melanoma Cutaneous Melanoma	PD-L1 expression PD-L1 expression	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: B - Late Trials	cemiplimab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials	tislelizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + bevacizumab Sensitive: B - Late Trials	nivolumab + bevacizumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	sintilimab Sensitive: B - Late Trials	sintilimab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: B - Late Trials	sintilimab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C1 - Off-label	nivolumab + ipilimumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	atezolizumab Sensitive: C1 - Off-label	atezolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label	nivolumab + ipilimumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Salivary Gland Cancer Salivary Gland Cancer	PD-L1 expression PD-L1 expression	Salivary Gland Cancer Salivary Gland Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Basal Cell Carcinoma BCC	PD-L1 expression PD-L1 expression	Basal Cell Carcinoma BCC	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Anal Carcinoma Anal Carcinoma	PD-L1 expression PD-L1 expression	Anal Carcinoma Anal Carcinoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Prostate Cancer Prostate Cancer	PD-L1 expression PD-L1 expression	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Squamous Cell Skin Cancer Squamous Cell Skin Cancer	PD-L1 expression PD-L1 expression	Squamous Cell Skin Cancer Squamous Cell Skin Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Prostate Cancer Prostate Cancer	PD-L1 expression PD-L1 expression	Prostate Cancer Prostate Cancer	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	PD-L1 expression PD-L1 expression	Ovarian Cancer Ovarian Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Solid Tumor Solid Tumor	PD-L1 expression PD-L1 expression	Solid Tumor Solid Tumor	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Solid Tumor Solid Tumor	PD-L1 expression PD-L1 expression	Solid Tumor Solid Tumor	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Kaposi Sarcoma Kaposi Sarcoma	PD-L1 expression PD-L1 expression	Kaposi Sarcoma Kaposi Sarcoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label	nivolumab + ipilimumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Melanoma Melanoma	PD-L1 expression PD-L1 expression	Melanoma Melanoma	atezolizumab Sensitive: C1 - Off-label	atezolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Melanoma Melanoma	PD-L1 expression PD-L1 expression	Melanoma Melanoma	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label